Please login to the form below

Not currently logged in
Email:
Password:

Cause of islet cell rejection identified

Researchers have pinpointed the mechanism responsible for early rejection of transplanted pancreatic islet cells in the treatment of type 1 diabetes

Japanese researchers at Riken and Fukuoka University have pinpointed the mechanism responsible for early rejection of transplanted pancreatic islet cells in the treatment of type 1 diabetes. A new system based on this mechanism has been shown to vastly increase transplant efficiency, setting the stage for the development of powerful new treatment techniques.

Islet cell transplantation, whereby insulin-producing cells from a donor pancreas are transplanted into the patient's liver, has achieved limited success due to a strong and rapid immune-mediated rejection of the transplanted islets.

With their discovery, the researchers have demonstrated that HMGB1 (high-mobility group box 1), a nuclear protein whose precise function has heretofore remained elusive, is in fact produced by the islet cells and directly triggers their early rejection. Based on this finding, they developed a system to measure the level of HMGB1 in the blood and determined the onset of rejection, information, which they used to establish a treatment four times more effective than earlier islet transplantation protocols.

While shedding light on a previously unknown function of a major nuclear protein, the discovery of the HMGB1-mediated pathway also represents a breakthrough in diabetes research. For millions of diabetes sufferers around the world, its application to islet transplantation promises great improvements in this technique, bringing dreams of insulin independence one step closer to reality.

This paper is published in the February issue of The Journal of Clinical Investigation

8th February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics